Achieve Life Sciences (ACHV) to Release Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) is expected to be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Achieve Life Sciences to post earnings of ($0.29) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.06). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Price Performance

Shares of Achieve Life Sciences stock opened at $2.97 on Tuesday. The stock has a market capitalization of $103.01 million, a price-to-earnings ratio of -2.63 and a beta of 1.67. The firm’s 50-day moving average price is $3.08 and its two-hundred day moving average price is $3.94. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. Achieve Life Sciences has a 1-year low of $2.51 and a 1-year high of $5.59.

Insider Transactions at Achieve Life Sciences

In other Achieve Life Sciences news, CFO Mark K. Oki purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $2.89 per share, with a total value of $28,900.00. Following the acquisition, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at approximately $28,900. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 2.00% of the stock is owned by company insiders.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.